Low pre-treatment neutrophil-to-lymphocyte ratio predicted a better survival in recurrent/metastatic cervical cancer treated with PD-1/PD-L1 inhibitors
The pre-treatment NLR could be a biomarker for predicting the response to anti-PD-1/PD-L1 therapy in recurrent/metastatic CC. In combination with PD-L1 status, it may improve the benefits of immunotherapy and lower the treatment costs.
Authors
- Ruixia Guo (ORCID: https://orcid.org/0000-0002-8847-2488)
- Jing Li (ORCID: https://orcid.org/0000-0003-3277-6818)
- Min Wang (ORCID: https://orcid.org/0000-0001-9670-6937)
- Yulu Wang (ORCID: https://orcid.org/0000-0002-8320-3529)
- Dian Wang (ORCID: https://orcid.org/0009-0004-1137-3248)
- Jiayu Pei (ORCID: https://orcid.org/0009-0005-5527-082X)
- Haifeng Qiu
Institutions
- First Affiliated Hospital of Zhengzhou University (CN)
Publication Details
- Journal
- Discover Oncology
- Published
- 2025-09-29
- DOI
- https://doi.org/10.1007/s12672-025-02862-z
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00